A detailed history of Algert Global LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 104,252 shares of TGTX stock, worth $3.08 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
104,252
Previous 147,218 29.19%
Holding current value
$3.08 Million
Previous $2.62 Million 6.91%
% of portfolio
0.07%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$17.21 - $25.28 $739,444 - $1.09 Million
-42,966 Reduced 29.19%
104,252 $2.44 Million
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $1.29 Million - $1.86 Million
97,118 Added 193.85%
147,218 $2.62 Million
Q1 2024

May 14, 2024

SELL
$13.02 - $21.3 $12,629 - $20,661
-970 Reduced 1.9%
50,100 $762,000
Q4 2023

Feb 14, 2024

SELL
$6.68 - $18.81 $37,341 - $105,147
-5,590 Reduced 9.87%
51,070 $872,000
Q3 2023

Nov 13, 2023

SELL
$8.36 - $26.5 $361,745 - $1.15 Million
-43,271 Reduced 43.3%
56,660 $474,000
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $980,673 - $2.22 Million
63,351 Added 173.18%
99,931 $2.48 Million
Q1 2023

May 12, 2023

SELL
$10.23 - $19.34 $1.54 Million - $2.91 Million
-150,449 Reduced 80.44%
36,580 $550,000
Q4 2022

Feb 13, 2023

BUY
$5.01 - $11.83 $394,387 - $931,257
78,720 Added 72.68%
187,029 $2.21 Million
Q3 2022

Nov 15, 2022

BUY
$4.57 - $8.4 $39,480 - $72,567
8,639 Added 8.67%
108,309 $641,000
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $372,765 - $1.06 Million
99,670 New
99,670 $424,000
Q1 2021

May 14, 2021

SELL
$41.61 - $54.3 $507,974 - $662,894
-12,208 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$25.27 - $54.9 $308,496 - $670,219
12,208 New
12,208 $635,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.